SEC Company Response from Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Jun 25, 2014
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: June 25, 2014 · CIK: 0001228627 · Accession: 0001140361-14-026641
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196255
Letter
VIA EDGAR Securities and Exchange Commission Attn: Jeffrey Riedler Re: Rexahn Pharmaceuticals, Inc. Shelf Registration Statement on Form S-3 (File No. 333-196255) Request for Acceleration of Effective Date
Dear Mr. Riedler:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Rexahn Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Shelf Registration Statement on Form S-3 (as amended to date, the “Shelf Registration Statement”) and declare the Shelf Registration Statement effective as of 4:00 PM, Eastern Time, on June 26, 2014, or as soon thereafter as possible.
In connection with this request for acceleration, the Company acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Rexahn Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm REXAHN PHARMACEUTICALS, INC. 15245 Shady Grove Road, Suite 455 Rockville, Maryland 20850 June 25, 2014 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Rexahn Pharmaceuticals, Inc. Shelf Registration Statement on Form S-3 (File No. 333-196255) Request for Acceleration of Effective Date Dear Mr. Riedler: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Rexahn Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Shelf Registration Statement on Form S-3 (as amended to date, the “Shelf Registration Statement”) and declare the Shelf Registration Statement effective as of 4:00 PM, Eastern Time, on June 26, 2014, or as soon thereafter as possible. In connection with this request for acceleration, the Company acknowledges that: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Rexahn Pharmaceuticals, Inc. /s/ Tae Heum Jeong By: Tae Heum Jeong Title: Senior Vice President and Chief Financial Officer